Article Figures & Data
Figures
- Figure 1.
Flow chart of patient selection. In total, 220 patients diagnosed with clinical stage II or III esophageal squamous cell carcinoma and underwent curative esophagectomy after neoadjuvant chemotherapy were eligible for inclusion. Of these, 22 patients were excluded: 13 patients who received triple chemotherapy in a clinical trial, eight patients who underwent non-curative resection, and one patient whose postoperative pathological diagnosis included neuroendocrine carcinoma. Finally, a total of 198 patients were included in this study. ESCC: Esophageal squamous cell carcinoma.
- Figure 2.
Recurrence-free survival (RFS) in the high and low IBL groups. The RFS in the high intraoperative blood loss (IBL) group was significantly poorer than that in the low IBL group (p=0.002, log-rank test).
- Figure 3.
Overall survival (OS) in the high and low intraoperative blood loss (IBL) groups. The OS in the high IBL group was significantly poorer than that in the low IBL group (p=0.010, log-rank test).
